BDSX (Biodesix) Tariff Resilience Score: 6/10 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDSX Biodesix Inc BDSX
53 GF Score
Price $22.36
GF Value $21.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Biodesix Tariff Resilience Score?

Biodesix BDSX -4.73% 53 Tariff Resilience Score is 6 as of Aug. 18, 2026. GuruFocus rates BDSX with a GF Score™ of 53/100 and a GF Value™ of $21.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Biodesix ranks better than 87.26% on this metric.

Biodesix has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Biodesix has Biodesix's diagnostic products have moderate exposure to tariffs. Its ability to source materials domestically and focus on the U.S. market provides some insulation from international trade issues.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biodesix might have Average Resilient.

Biodesix  (NAS:BDSX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biodesix Tariff Resilience Score Related Terms

BDSX vs IMDX, XGN, BNR: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Biodesix's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodesix Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Biodesix's Tariff Resilience Score falls into.


BDSX
53GF Score
Biodesix Inc BDSX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Biodesix (BDSX) has a Tariff Resilience Score of 6 as of Aug. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Biodesix ranks #27 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 12.7%.
Is Biodesix's Tariff Resilience Score too high?
Biodesix's current Tariff Resilience Score is 6. Based on the distribution chart, Biodesix ranks #27 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Biodesix has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's Tariff Resilience Score compare to IMDX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Biodesix ranks #27 out of 212 companies for Tariff Resilience Score. This places Biodesix in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Biodesix's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Fairly Valued. The stock's GF Value™ is $21.33, compared to a current price of $22.36 — trading 4.8% above its estimated fair value. The current Tariff Resilience Score is 6. Biodesix's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Biodesix (BDSX), the current Tariff Resilience Score is 6 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodesix (BDSX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodesix stock appears to be overvalued. The current stock price of $22.36 is trading 4.8% above its estimated GF Value™ of $21.33. GuruFocus considers Biodesix to be Fairly Valued.

Key valuation signals for BDSX:

  • Tariff Resilience Score: 6
  • GF Value™: $21.33 vs. price of $22.36 (4.8% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodesix Business Description

Address 919 West Dillon Road, Louisville, CO, USA, 80027
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
53GF Score

Get the complete analysis for BDSX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.36
Price
$21.33
GF Value